Stock Market Reviews

EKSO (Ekso Bionics Holdings, Inc.) News

Get the latest news, insights, and market updates on EKSO (Ekso Bionics Holdings, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Financials, Consumer Discretionary Push US Equity Indexes Lower
  US equity indexes were lower after midday Tuesday, with financials, consumer discretionary, and cons
  Dec 30, 2025 - $EKSO
• Stocks to Watch Tuesday: Boeing, Meta, Applied Digital, Pop Mart
  ↗️ Applied Digital (APLD): The artificial-intelligence infrastructure provider plans to spin out its cloud business and combine it with EKSO Bionics (EKSO). Shares in Applied Digital closed down 2.9%, while EKSO shares surged 94%.
  Dec 30, 2025 - $EKSO
• Applied Digital to Spin Out Cloud Business, Proposes Business Combination with EKSO to Launch ChronoScale
  Proposed Business Combination with Nasdaq-listed EKSO to Form an Accelerated Focused GPU Platform Purpose Built for Next-Generation AI WorkloadsDALLAS, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Applied Digital (NASDAQ: APLD), a designer, builder, and operator of high-performance, sustainably engineered data centers and colocation services for artificial intelligence, cloud, networking and blockchain workloads, and EKSO Bionics Holdings, Inc. (Nasdaq: EKSO) (“EKSO”) announced today that Applied Digital a
  Dec 29, 2025 - $EKSO
• Ekso Bionics Inks Agreement to Become the Exclusive U.S. Distributor of MediTouch’s Groundbreaking BalanceTutor™ Rehabilitation System
  SAN RAFAEL, Calif. and TNUVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has entered into an agreement with Israel-based MediTouch Inc. (“MediTouch”) to become the exclusive authorized sales agent and distributor of MediTouch’s BalanceTutor™ rehabilitation system in the United States. The BalanceTutor is the only known
  Dec 4, 2025 - $EKSO
• How Recent Moves Are Rewriting the Story for Ekso Bionics
  Ekso Bionics Holdings has seen its consensus analyst price target increase from $6.75 to $7.75, reflecting a shift in expectations for the company's future performance. This change comes alongside a slight decrease in the discount rate and improved revenue growth assumptions, which indicates greater confidence in the company's long-term prospects. Stay tuned to discover how you can stay ahead of updates in Ekso Bionics Holdings' evolving narrative. Analyst Price Targets don't always capture...
  Nov 28, 2025 - $EKSO
• Ekso Bionics (EKSO) Upgraded to Buy: Here's Why
  Ekso Bionics (EKSO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
  Nov 21, 2025 - $EKSO
• Ekso Bionics Announces $3.7 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules
  SAN RAFAEL, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that on October 28, 2025, it entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 769,490 shares of the Company’s common stock at a purchase price of $4.81 per share of common stock in a registered direct offering priced at-the-market un
  Oct 29, 2025 - $EKSO
• Ekso Bionics: Q3 Earnings Snapshot
  SAN RAFAEL, Calif. AP) — Ekso Bionics Holdings Inc. EKSO) on Tuesday reported a loss of $1.4 million in its third quarter.
  Oct 28, 2025 - $EKSO
• Ekso Bionics Reports Third Quarter 2025 Financial Results
  SAN RAFAEL, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and nine months ended September 30, 2025. Third Quarter 2025 Highlights and Accomplishments Revenue grew 2% year-over-year and rebounded 105% sequentially quarter-over-quarter to $4.2 millionGross margin increased 680 basis points year-over-yea
  Oct 28, 2025 - $EKSO
• Ekso Bionics (EKSO) Upgraded to Buy: Here's What You Should Know
  Ekso Bionics (EKSO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
  Sep 26, 2025 - $EKSO